Literature DB >> 19850491

Does chronic obstructive pulmonary disease affect postoperative quality of life in patients undergoing lobectomy for lung cancer? A case-matched study.

Cecilia Pompili1, Alessandro Brunelli, Majed Refai, Francesco Xiumè, Armando Sabbatini.   

Abstract

BACKGROUND: The objective of this investigation was to assess the quality of life (QoL) before and after pulmonary lobectomy in patients with chronic obstructive pulmonary disease (COPD) and to compare these values with a case-matched population of patients with normal respiratory function.
METHODS: This is an observational analysis performed on a prospective dataset of 220 consecutive patients submitted to pulmonary lobectomy for lung cancer (2006-2008). Patients submitted to extended procedures (chest wall resection and superior sulcus) were excluded from the analysis. Pre- and postoperative (3 months) QoL were assessed in all patients through the administration of the Short Form 36v2 (SF36v2) health survey, a generic QoL instrument assessing eight health physical and mental concepts. Propensity score was used to match COPD patients (according to the NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria: forced expiratory volume in 1s/forced expiratory vital capacity (FEV1/FVC) ratio <0.7 and FEV1 <80%) with counterparts without COPD. QoL scales were compared between the two matched groups by means of the Mann-Whitney test.
RESULTS: Propensity score yielded 50 well-matched pairs of patients with and without COPD. Compared with non-COPD patients, those with COPD had a threefold higher rate of cardiopulmonary morbidity (14 cases vs 5 cases, 28% vs 10%, p=0.04), lower reduction in FEV1 (6% vs 13%, p=0.0002), but lower residual postoperative FEV1 values (62% vs 74%, p<0.0001). Postoperative carbon monoxide lung diffusion capacity (DLCO) (69% vs 65%, p=0.1) and VO(2 max) (15.3 ml kg(-1)min(-1) vs 14.3 ml kg(-1)min(-1)p=0.4) values were similar between the groups. Although most of the preoperative and postoperative QoL domains in both groups were reduced compared with normal population (<50), we were not able to find differences between the groups in any of the preoperative and postoperative physical and mental QoL scales.
CONCLUSIONS: The evidence of an acceptable QoL in COPD patients may help both patients and physicians in the surgical decision-making process in the face of high rates of complications. Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19850491     DOI: 10.1016/j.ejcts.2009.09.025

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  19 in total

1.  Worse Prognosis for Stage IA Lung Cancer Patients with Smoking History and More Severe Chronic Obstructive Pulmonary Disease.

Authors:  Yukihiro Yoshida; Hidenori Kage; Tomohiro Murakawa; Yasunori Sato; Satoshi Ota; Masashi Fukayama; Jun Nakajima
Journal:  Ann Thorac Cardiovasc Surg       Date:  2015-01-26       Impact factor: 1.520

2.  Long-term respiratory function recovery in patients with stage I lung cancer receiving video-assisted thoracic surgery versus thoracotomy.

Authors:  Tae Yun Park; Young Sik Park
Journal:  J Thorac Dis       Date:  2016-01       Impact factor: 2.895

3.  The Six-Minute-Walk Test in assessing respiratory function after tumor surgery of the lung: a cohort study.

Authors:  Oliver Rick; Tsegaye Metz; Michael Eberlein; Joachim Schirren; Servet Bölükbas
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

4.  Patient reported outcomes following video assisted thoracoscopic (VATS) resection or stereotactic ablative body radiotherapy (SABR) for treatment of non-small cell lung cancer: protocol for an observational pilot study (LiLAC).

Authors:  Cecilia Pompili; Kevin N Franks; Alessandro Brunelli; Yusuf S Hussain; Patricia Holch; Matthew E Callister; Jonathan M Robson; Kostas Papagiannopoulos; Galina Velikova
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

5.  Regional Emphysema Score Predicting Overall Survival, Quality of Life, and Pulmonary Function Recovery in Early-Stage Lung Cancer Patients.

Authors:  Jie Dai; Ming Liu; Stephen J Swensen; Shawn M Stoddard; Jason A Wampfler; Andrew H Limper; Gening Jiang; Ping Yang
Journal:  J Thorac Oncol       Date:  2017-01-23       Impact factor: 15.609

Review 6.  Quality of life after lung resection for lung cancer.

Authors:  Cecilia Pompili
Journal:  J Thorac Dis       Date:  2015-04       Impact factor: 2.895

Review 7.  A guide for managing patients with stage I NSCLC: deciding between lobectomy, segmentectomy, wedge, SBRT and ablation-part 2: systematic review of evidence regarding resection extent in generally healthy patients.

Authors:  Frank C Detterbeck; Vincent J Mase; Andrew X Li; Ulas Kumbasar; Brett C Bade; Henry S Park; Roy H Decker; David C Madoff; Gavitt A Woodard; Whitney S Brandt; Justin D Blasberg
Journal:  J Thorac Dis       Date:  2022-06       Impact factor: 3.005

8.  Video-assisted thoracoscopic lobectomy for non-small cell lung cancer in patients with severe chronic obstructive pulmonary disease.

Authors:  Wei Wang; Zhiqiang Xu; Xinguo Xiong; Weiqiang Yin; Xin Xu; Wenlong Shao; Hanzhang Chen; Jianxing He
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

9.  European Society of Thoracic Surgeons electronic quality of life application after lung resection: field testing in a clinical setting.

Authors:  Cecilia Pompili; Jason Trevis; Miriam Patella; Alessandro Brunelli; Lidia Libretti; Nuria Novoa; Marco Scarci; Sara Tenconi; Joel Dunning; Stefano Cafarotti; Michael Koller; Galina Velikova; Yaron Shargall; Federico Raveglia
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-27

10.  Effect of comorbidities on long-term outcomes after thoracoscopic surgery for stage I non-small cell lung cancer patients with chronic obstructive pulmonary disease.

Authors:  Takamasa Shibazaki; Makoto Odaka; Yuki Noda; You Tsukamoto; Shohei Mori; Hisatoshi Asano; Makoto Yamashita; Toshiaki Morikawa
Journal:  J Thorac Dis       Date:  2018-02       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.